scholarly journals Proportions of Cancer Cases in Primary Care, Hospital, and Cancer Registry Data Among Patients Treated for Overactive Bladder

Epidemiology ◽  
2019 ◽  
Vol 30 (2) ◽  
pp. e8-e9
Author(s):  
Andrea V. Margulis ◽  
Joan Fortuny ◽  
James A. Kaye ◽  
Brian Calingaert ◽  
Maria Reynolds ◽  
...  
Epidemiology ◽  
2018 ◽  
pp. 1
Author(s):  
Andrea V Margulis ◽  
Joan Fortuny ◽  
James A Kaye ◽  
Brian Calingaert ◽  
Maria Reynolds ◽  
...  

Author(s):  
Sophia Amjad ◽  
Rachael Williams ◽  
Rachael Brannan ◽  
Tariq Malik ◽  
Janet Valentine

ABSTRACTObjectivesTo enhance the research value and capability of its primary care database, the Clinical Practice Research Datalink (CPRD) has collaborated with Public Health England (PHE)’s National Cancer Registration and Analysis Service to facilitate access to linked cancer registration data for use in research, pharmacovigilance, drug monitoring and health outcomes analysis. Since 2009, access to this linked resource has been co-managed by CPRD and PHE, through two parallel, independent approvals processes: (a) the MHRA Independent Scientific Advisory Committee (ISAC) and (b) the PHE Office for Data Release (ODR). In upholding the Office for Life Science Ministerial Industry Strategy Group (Health Data Programme)’s vision to minimise process barriers to accessing real world data, CPRD and PHE have worked together to unify and streamline these two processes into a single end-to-end application and approval process. ApproachEach organisation reviewed each other’s approval processes to achieve an improved mutual understanding of the respective organisation’s governance approach, the risk based assessments applied to disclosure risk, risk appetites and policies, with the goal to harmonise these into a single approval process. ResultsCPRD and PHE are finalising a contract establishing a clear operating framework allowing CPRD to grant approval to researchers for the use of linked cancer registry data. The contract names CPRD as a joint data controller and sets out the purposes for processing, the manner of processing and the means by which joint data controller responsibilities will be satisfied. An associated service level agreement is in discussion which will enable robust timelines and performance management for both organisations. These developments are important milestones towards achieving the single approval process by allowing CPRD to review applications for cancer registry data in-house, simultaneously to the ISAC review. ConclusionThe strong relationship built between CPRD and PHE, and willingness to develop a single application and approval process, will strengthen and streamline access to these data, whilst assuring patients and the public that scientific integrity is maintained and proportionate information governance checks are in place. Upon completion of this work, applicants will experience associated faster review and feedback time, ultimately leading to faster approvals. Researchers wishing to utilise these linked data will soon be able to submit one application to ISAC, have one point of contact and one approval.


Author(s):  
Julie Chas ◽  
Marine Nadal ◽  
Martin Siguier ◽  
Anne Fajac ◽  
Michel Denis ◽  
...  

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Maximilian Richter ◽  
Lena Sonnow ◽  
Amir Mehdizadeh-Shrifi ◽  
Axel Richter ◽  
Rainer Koch ◽  
...  

Abstract Objectives To evaluate how the certification of specialised Oncology Centres in Germany affects the relative survival of patients with colorectal cancer (CRC) by means of national and international comparison. Methods Between 2007 and 2013, 675 patients with colorectal cancer, treated at the Hildesheim Hospital, an academic teaching hospital of the Hannover Medical School (MHH), were included. A follow-up of the entire patient group was performed until 2014. To obtain international data, a SEER-database search was done. The relative survival of 148,957 patients was compared to our data after 12, 36 and 60 months. For national survival data, we compared our rates with 41,988 patients of the Munich Cancer Registry (MCR). Results Relative survival at our institution tends to be higher in advanced tumour stages compared to national and international cancer registry data. Nationally we found only little variation in survival rates for low stages CRC (UICC I and II), colon, and rectal cancer. There were notable variations regarding relative survival rates for advanced CRC tumour stages (UICC IV). These variations were even more distinct for rectal cancer after 12, 36 and 60 months (Hildesheim Hospital: 89.9, 40.3, 30.1%; Munich Cancer Registry (MCR): 65.4, 28.7, 16.6%). The international comparison of CRC showed significantly higher relative survival rates for patients with advanced tumour stages after 12 months at our institution (77 vs. 54.9% for UICC IV; raw p<0.001). Conclusions Our findings suggest that patients with advanced tumour stages of CRC and especially rectal cancer benefit most from a multidisciplinary and guidelines-oriented treatment at Certified Oncology Centres. For a better evaluation of cancer treatment and improved national and international comparison, the creation of a centralised national cancer registry is necessary.


2020 ◽  
Vol 128 (10) ◽  
pp. 107004
Author(s):  
Nathan C. Coleman ◽  
Richard T. Burnett ◽  
Majid Ezzati ◽  
Julian D. Marshall ◽  
Allen L. Robinson ◽  
...  

Medical Care ◽  
2000 ◽  
Vol 38 (11) ◽  
pp. 1131-1140 ◽  
Author(s):  
John M. Brooks ◽  
Elizabeth Chrischilles ◽  
Shane Scott ◽  
Jane Ritho ◽  
Shari Chen-Hardee

2009 ◽  
Vol 124 (10) ◽  
pp. 2391-2399 ◽  
Author(s):  
Laura M. Woods ◽  
Bernard Rachet ◽  
Dianne O'Connell ◽  
Gill Lawrence ◽  
Elizabeth Tracey ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document